Alefacept. Biogen.
Alefacept is a lymphocyte function-associated antigen-3/IgG1 fusion protein that inhibits T-cells by antagonizing CD2, which has been developed and launched by Biogen for the potential treatment of psoriasis. In February 2003, Biogen launched alefacept in the US for use in adults with moderate-to-severe chronic plaque psoriasis, and by March 2003, the company was preparing for psoriasis trials to commence in Japan by the end of December 2003.
Ormerod
Anthony D
AD
Aberdeen University and University Hospitals, Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK. a.d.ormerod@arh.grampian.scot.nhs.uk
D000077944:Alefacept; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D018968:CD58 Antigens / Q000627:therapeutic use; D006801:Humans; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018968:CD58 Antigens; D011993:Recombinant Fusion Proteins; D000077944:Alefacept